サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1757974

抗血栓薬の世界市場

Antithrombotic Drugs

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
抗血栓薬の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗血栓薬の世界市場は2030年までに759億米ドルに達する見込み

2024年に514億米ドルと推定された抗血栓薬の世界市場は、分析期間2024-2030年にCAGR 6.7%で成長し、2030年には759億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口ルートは、CAGR 8.1%を記録し、分析期間終了時には495億米ドルに達すると予想されます。注射剤ルートセグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は140億米ドルと推定、中国はCAGR 10.8％で成長予測

米国の抗血栓薬市場は2024年に140億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに160億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.6%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の抗血栓薬市場- 主要動向と促進要因のまとめ

抗血栓薬が心血管および血栓性疾患の現代的管理に不可欠な理由とは？

抗血栓薬は、特に血栓塞栓症の予防と治療において、現代医療に欠かせないものとなっています。抗凝固薬、抗血小板薬、線溶薬などを含むこれらの薬剤は、心房細動、深部静脈血栓症（DVT）、肺塞栓症、人工股関節置換術や心臓弁植え込み術などの手術を受けた患者など、リスクの高い人々の血栓予防に広く使用されています。座りがちな生活習慣、肥満、高血圧、糖尿病などに起因する心血管疾患（CVD）の世界の増加に伴い、効果的な血栓症予防に対する需要はかつてないほど高まっています。抗血栓薬は、心筋梗塞や虚血性脳卒中などの急性疾患の管理にも不可欠であり、血栓の予防や溶解を適時に行うことが救命につながります。長期的な二次予防戦略における抗血栓薬の役割は、すでに血栓イベントを経験した患者を再発から確実に守ることです。さらに、血栓形成のリスクに関するヘルスケアプロバイダーと患者の意識の高まりは、より広範で積極的な処方パターンにつながっています。主要な医療機関の臨床ガイドラインは、現在、抗血栓療法を多くの適応症に対する標準治療として推奨しており、その医療上の必要性が強化されています。人口の高齢化と併存疾患の増加に伴い、抗血栓療法の対象となる患者層は拡大し続けており、急性期医療と慢性期医療の両モデルにおいて抗血栓療法が重要な役割を担っていることが世界的に明らかになっています。

科学的・薬学的進歩は抗血栓療法の安全性と有効性をどのように向上させているか？

薬理学と薬剤開発における飛躍的な進歩により、より安全で有効性が高く、患者に優しい抗血栓療法が進化しています。ワルファリンやヘパリンのような従来の薬剤は抗凝固療法の主役であったが、治療域の狭さ、頻繁なモニタリング、食事や薬物との相互作用などの課題がありました。これに対し，新世代の抗凝固薬，特にアピキサバン，リバーロキサバン，エドキサバン，ダビガトランなどの直接経口抗凝固薬（DOACs）がこの分野に革命をもたらしました。これらの薬剤は、予測可能な薬物動態、一定量の投与、定期的な血液検査の必要性の低減を提供し、患者のアドヒアランスとQOLを大幅に改善します。プラスグレルやチカグレロルのような先進的抗血小板薬は、クロピドグレルのような旧来の薬剤と比較して、特定の高リスク心血管系において優れた治療成績を実証しています。さらに、緊急時や手術時の安全性を高める可逆性薬剤や解毒剤の開発にも、製薬研究はますます力を注いでいます。例えば、イダルシズマブやアンデキサネット・アルファは現在、DOACの可逆剤として承認されており、出血リスクに関する以前の懸念に対処しています。ナノテクノロジーと標的ドラッグデリバリーシステムは、抗血栓薬の局在化と放出制御を最適化し、全身への曝露を最小限に抑え、副作用を軽減するために研究されています。さらに、薬理ゲノミクスと実データ解析の進歩に支えられ、患者固有のリスクプロファイルに合わせた併用療法が注目されています。このような科学的開発は、治療の選択肢を広げるだけでなく、より個別化された正確な治療プロトコルを可能にし、臨床医の血栓リスク管理への取り組み方を再構築しています。

人口動態および臨床動向は、抗血栓薬の需要拡大をどのように形成しているか？

慢性疾患の世界の負担増と人口の高齢化は、抗血栓薬市場の形成に極めて重要な役割を果たしています。高齢者は血管の老化、運動能力の低下、心房細動や静脈血栓塞栓症のような疾患の有病率の高さにより、血栓性イベントの影響を受けやすくなっています。このような人口動態の動向だけで、予防的および治療的抗血栓療法を必要とする患者層は着実に拡大しています。さらに、高度な画像診断、日常的なスクリーニング、ウェアラブルヘルス技術による心血管疾患の発見と診断の増加は、抗血栓薬を含む治療プロトコールの早期開始に寄与しています。欧米型の食生活と座りがちなライフスタイルの世界化により、新興国では糖尿病、肥満、高血圧が急増しており、以前はリスクが低いと考えられていた地域での需要がさらに高まっています。外科手術も、より低侵襲な手術、臓器移植、がん治療など、血栓リスクを高め、予防的抗血栓療法を必要とするものへと進化しています。例えばがん治療では、がんに関連した血栓症は重大な合併症として認識されるようになり、特定の患者集団では抗血栓療法が日常的に行われるようになっています。さらに、COVID-19の大流行により、重症ウイルス感染と凝固障害との関連が浮き彫りになり、入院患者における抗凝固薬の使用が拡大し、従来の適応を超えた血栓リスクに対する認識が高まりました。このような人口統計学的要因と臨床的要因の収束は、抗血栓薬に対する持続的な世界的需要を生み出し、ヘルスケアシステムに対して、抗凝固薬へのアクセスを向上させ、抗凝固薬を合理的に使用するためのガイドラインを最適化するよう促しています。

抗血栓薬市場の世界的拡大の主な促進要因は？

抗血栓薬市場の成長の原動力は、世界中の循環器・血液医療を再構築している医療、技術、規制、経済的要因の相乗効果です。最も強力な促進要因の一つは、非伝染性疾患、特に世界死亡率の大きな割合を占める心血管疾患への世界の疫学的移行です。DOACの開発と普及は、従来の抗凝固剤に代わるより安全で利便性の高い選択肢を提供することで、患者のコンプライアンスと臨床応用の両方を拡大し、市場の展望を一変させました。強固な臨床試験データと迅速な承認取得メカニズムに支えられた新規薬剤の規制当局による承認は、複数の地域で市場浸透を加速させています。さらに、新興諸国におけるヘルスケア・インフラの拡充により、抗血栓薬を含む救命薬へのアクセスが拡大しており、多くの場合、政府が支援する保険制度や公衆衛生イニシアチブによって支えられています。出血リスクを低減した次世代薬剤の追求など、製薬業界による研究開発への投資は、イノベーションを促進し続けています。遠隔医療やデジタルヘルス技術も、抗血栓療法を受ける患者の遠隔モニタリングを容易にし、アドヒアランスと安全性を向上させることで貢献しています。心房細動における脳卒中予防、術後の血栓予防、心血管イベントの長期二次予防などの標準化されたケアパスへの抗血栓治療の統合も重要な推進力となっています。学術的協力、医師教育の強化、一般市民の意識向上キャンペーンが、市場プロファイルをさらに高めています。これらの市場促進要因が相まって、世界の抗血栓薬市場は力強く持続的な成長を遂げており、成熟したヘルスケア経済圏と新興ヘルスケア経済圏の両方で継続的な拡大を確実なものにしています。

セグメント

投与ルート（経口ルート、注射ルート）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全48件）

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline（GSK）
  • Johnson & Johnson
  • Medtronic
  • Mylan（now part of Viatris）
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36180

Global Antithrombotic Drugs Market to Reach US$75.9 Billion by 2030

The global market for Antithrombotic Drugs estimated at US$51.4 Billion in the year 2024, is expected to reach US$75.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Oral Route, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$49.5 Billion by the end of the analysis period. Growth in the Injectable Route segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Antithrombotic Drugs market in the U.S. is estimated at US$14.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Antithrombotic Drugs Market - Key Trends & Drivers Summarized

Why Are Antithrombotic Drugs Crucial in the Modern Management of Cardiovascular and Thrombotic Disorders?

Antithrombotic drugs have become an indispensable part of contemporary medicine, particularly in the prevention and treatment of thromboembolic disorders, which are among the leading causes of morbidity and mortality worldwide. These drugs-which include anticoagulants, antiplatelet agents, and fibrinolytics-are widely used to prevent blood clots in high-risk populations such as patients with atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, and those who have undergone surgeries like hip replacement or heart valve implantation. With the global rise in cardiovascular diseases (CVDs), driven by sedentary lifestyles, obesity, hypertension, and diabetes, the demand for effective thrombosis prevention is higher than ever. Antithrombotics are also vital in managing acute conditions such as myocardial infarction and ischemic stroke, where timely clot prevention or dissolution can be life-saving. Their role in long-term secondary prevention strategies ensures that patients who have already experienced clotting events remain protected from recurrence. Moreover, increasing awareness among both healthcare providers and patients about the risks of clot formation has led to broader and more proactive prescribing patterns. Clinical guidelines from leading health authorities now recommend antithrombotic therapy as a standard of care for numerous indications, reinforcing their medical necessity. As populations age and comorbidities become more common, the patient base eligible for antithrombotic therapy continues to expand, underscoring the drugs’ critical role in both acute and chronic care models globally.

How Are Scientific and Pharmaceutical Advances Improving the Safety and Efficacy of Antithrombotic Therapies?

Significant strides in pharmacology and drug development have led to the evolution of safer, more effective, and more patient-friendly antithrombotic therapies. While traditional agents such as warfarin and heparin have long been mainstays of anticoagulant therapy, they present challenges like narrow therapeutic windows, frequent monitoring, and dietary or drug interactions. In response, a new generation of antithrombotic drugs-particularly direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran-has revolutionized the field. These agents offer predictable pharmacokinetics, fixed dosing, and reduced need for routine blood testing, significantly improving patient adherence and quality of life. Advanced antiplatelet agents like prasugrel and ticagrelor have demonstrated superior outcomes in certain high-risk cardiovascular settings compared to older drugs like clopidogrel. Additionally, pharmaceutical research is increasingly focused on developing reversible agents and antidotes that enhance safety during emergency situations or surgeries. For example, idarucizumab and andexanet alfa are now approved as reversal agents for DOACs, addressing earlier concerns about bleeding risks. Nanotechnology and targeted drug delivery systems are being explored to optimize the localization and controlled release of antithrombotic agents, minimizing systemic exposure and reducing side effects. Furthermore, combination therapies tailored to patient-specific risk profiles are gaining attention, supported by advances in pharmacogenomics and real-world data analytics. These scientific developments are not only expanding the range of therapeutic options but are also enabling more personalized and precise treatment protocols, reshaping how clinicians approach thrombotic risk management.

How Are Demographic and Clinical Trends Shaping the Growing Demand for Antithrombotic Drugs?

The rising global burden of chronic conditions and aging populations is playing a pivotal role in shaping the antithrombotic drugs market. Older adults are significantly more susceptible to thrombotic events due to vascular aging, reduced mobility, and higher prevalence of conditions like atrial fibrillation and venous thromboembolism. This demographic trend alone has created a steadily expanding patient pool in need of both preventive and curative antithrombotic therapy. Additionally, the increased detection and diagnosis of cardiovascular diseases through advanced imaging, routine screenings, and wearable health technologies have contributed to earlier initiation of treatment protocols that include antithrombotics. The globalization of Western diets and sedentary lifestyles has led to a sharp rise in diabetes, obesity, and hypertension in emerging economies, further boosting demand in regions previously considered low-risk. Surgical practices have also evolved to include more minimally invasive procedures, organ transplants, and cancer treatments-all of which can increase thrombotic risk and require prophylactic antithrombotic therapy. In oncology, for example, cancer-associated thrombosis is now recognized as a significant complication, prompting routine antithrombotic use in certain patient populations. Furthermore, the COVID-19 pandemic highlighted the association between severe viral infections and coagulopathy, leading to wider use of anticoagulants in hospitalized patients and raising awareness of thrombotic risks beyond traditional indications. This convergence of demographic and clinical factors is creating sustained, global demand for antithrombotic drugs, compelling healthcare systems to enhance access and optimize guidelines for their rational use.

What Are the Key Drivers Behind the Global Expansion of the Antithrombotic Drugs Market?

The growth in the antithrombotic drugs market is driven by a synergy of medical, technological, regulatory, and economic factors that are reshaping cardiovascular and hematological care across the globe. One of the most powerful drivers is the global epidemiological transition toward non-communicable diseases, particularly cardiovascular disorders, which account for a significant share of global mortality. The development and widespread acceptance of DOACs have transformed the market landscape by offering safer, more convenient alternatives to traditional anticoagulants, thereby expanding both patient compliance and clinical applications. Regulatory approvals for newer agents, supported by robust clinical trial data and fast-track mechanisms, have accelerated market penetration in multiple regions. Additionally, expanded healthcare infrastructure in developing countries is enabling greater access to life-saving drugs, including antithrombotics, often supported by government-sponsored insurance programs and public health initiatives. The pharmaceutical industry’s investment in R&D, including the pursuit of next-generation agents with reduced bleeding risk, continues to fuel innovation. Telemedicine and digital health technologies are also contributing by facilitating remote monitoring of patients on antithrombotic therapy, improving adherence and safety. Another key driver is the integration of antithrombotic treatment into standardized care pathways for conditions such as stroke prevention in atrial fibrillation, postoperative thromboprophylaxis, and long-term secondary prevention of cardiovascular events. Academic collaborations, increased physician education, and heightened public awareness campaigns are further elevating the market profile. Combined, these drivers are generating strong and sustained growth in the global antithrombotic drugs market, ensuring its continued expansion across both mature and emerging healthcare economies.

SCOPE OF STUDY:

The report analyzes the Antithrombotic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Route, Injectable Route); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan (now part of Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Antithrombotic Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Cardiovascular and Thromboembolic Events Throws the Spotlight on Antithrombotics
    • Use in Stroke, DVT, PE, and Post-Operative Prevention Supports High Clinical Adoption
    • OEMs Offering Novel Oral Anticoagulants (NOACs) Improve Patient Compliance and Risk Profiles
    • Expansion of Indications Across Atrial Fibrillation and Cancer-Associated Thrombosis Drives Volume
    • OEM Innovation in Fixed-Dose, Low-Monitoring Drugs Enhances Outpatient Management
    • Growing Demand for Antiplatelet Agents in Secondary Prevention Enhances Therapeutic Breadth
    • Use of D-Dimer Testing and Diagnostic Algorithms Supports Risk Stratification and Timely Initiation
    • Focus on Rapid-Onset and Short Half-Life Drugs Address Surgical Bridging Needs
    • Use in Geriatric Populations With Polypharmacy Concerns Drives Development of Safer Alternatives
    • Growth in Extended Prophylaxis in Orthopedic and Cancer Surgery Enhances Institutional Use
    • OEM Investment in Combination Anticoagulant-Antiplatelet Regimens Expands Therapeutic Efficacy
    • Increased Digital Health Integration for Dosing Support and Monitoring Adds Patient Management Value
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antithrombotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • JAPAN
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CHINA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • EUROPE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • FRANCE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • GERMANY
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • INDIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AFRICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030

IV. COMPETITION